dr. monk on trabectedin for ovarian cancer
Published 10 years ago • 254 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
2:08
dr. monk discusses individualized treatments and clinical trial endpoints in ovarian cancer
-
0:53
dr. monk on combination therapies in patients with ovarian cancer
-
1:47
dr. monk on the utility of bevacizumab for cervical cancer
-
1:58
dr. monk on the design and results of the trinova-1 trial
-
2:26
dr. monk on bevacizumab plus a vda in ovarian, tubal, or peritoneal carcinoma
-
2:35
dr. monk on choosing between parp inhibitors in ovarian cancer
-
0:54
jonathan c. trent, md, phd: clinical data supporting the use of trabectedin
-
1:29
dr. monk on the fda approval of maintenance rucaparib in ovarian cancer
-
1:48
dr. monk on trial endpoints for ovarian cancer agents
-
3:48
targeted therapy in newly diagnosed advanced ovarian cancer
-
5:06
monitoring and managing patients with ovarian cancer
-
1:58
initial and maintenance treatments for ovarian cancer
-
4:38
managing toxicities in ovarian cancer treatments
-
4:30
ovarian cancer: therapeutic management at recurrence
-
1:56
dr. monk discusses immunotherapy in ovarian cancer
-
4:31
maintenance therapy for advanced ovarian cancer
-
1:30
dr. monk on bevacizumab in recurrent cervical cancer
-
1:29
a 54-year-old female with ovarian cancer
-
2:11
approaching frontline therapy options for ovarian cancer